Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gains from Investment Securities: 2021-2024

Historic Gains from Investment Securities for Monte Rosa Therapeutics (GLUE) over the last 4 years, with Dec 2024 value amounting to $11.6 million.

  • Monte Rosa Therapeutics' Gains from Investment Securities rose 29.39% to $15.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.2 million, marking a year-over-year increase of 29.39%. This contributed to the annual value of $11.6 million for FY2024, which is 23.36% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Gains from Investment Securities of $11.6 million as of FY2024, which was up 23.36% from $9.4 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Gains from Investment Securities high stood at $11.6 million for FY2024, and its period low was -$17,000 during FY2021.
  • Its 3-year average for Gains from Investment Securities is $7.0 million, with a median of $9.4 million in 2023.
  • Data for Monte Rosa Therapeutics' Gains from Investment Securities shows a peak YoY soared of 8,519.20% (in 2023) over the last 5 years.
  • Over the past 4 years, Monte Rosa Therapeutics' Gains from Investment Securities (Yearly) stood at -$17,000 in 2021, then spiked by 741.18% to $109,000 in 2022, then soared by 8,519.20% to $9.4 million in 2023, then increased by 23.36% to $11.6 million in 2024.